

1 **Relationship between circulating FSH levels and body composition and bone health in patients with**
2 **prostate cancer who undergo androgen deprivation therapy. The BLADE study.**

3 Bergamini M¹, Dalla Volta A¹, Palumbo C², Zamboni S³, Triggiani L⁴, Zamparini M¹, Laganà M¹, Rinaudo L⁵, Di
4 Meo N⁶, Caramella I¹, Bresciani R⁷, Valcamonico F¹, Borghetti P⁴, Guerini A⁴, Farina D⁶, Antonelli A⁸, Simeone
5 C³, Mazziotti G^{9,10}, Berruti A¹.

6 1. Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological
7 Sciences and Public Health, University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.

8 2. Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore
9 Della Carità Hospital, Novara, Italy.

10 3. Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences
11 and Public Health, University of Brescia, Brescia, Italy.

12 4. Radiation Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological
13 Sciences and Public Health, University of Brescia, Brescia, Italy.

14 5. Tecnologie Avanzate S.r.l., Turin, Italy.

15 6. Radiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences
16 and Public Health, University of Brescia, Brescia, Italy.

17 7. Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University of
18 Brescia, Brescia, Italy.

19 8. Urology Unit, AOUI Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of
20 Verona, Verona, Italy.

21 9. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.

22 10. Endocrinology, Diabetology and Medical Andrology Unit, Metabolic Bone Diseases and Osteoporosis
23 Section, IRCCS Humanitas Research Hospital, Rozzano-Milan Italy.

24

25 **Correspondence to:**

26 Gherardo Mazziotti
27 Department of Biomedical Sciences
28 Humanitas University
29 Via Rita Levi Montalcini 4
30 20072 Pieve Emanuele, Milan
31 Italy

32

33

34 Alberto Dalla Volta
35 Medical Oncology Unit
36 ASST-Spedali Civili
37 Piazzale Spedali Civili 1
38 25123 Brescia
39 Italy

40

41

42 **Key words:** prostate cancer patients, androgen deprivation, FSH, body composition, bone health

43 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 **Abstract**

45 *Background:* Amongst its extragonadal effects, Follicle-Stimulating Hormone (FSH) has an impact on body
46 composition and bone metabolism. Since androgen deprivation therapy (ADT) has a profound impact on
47 circulating FSH concentrations, this hormone could potentially be implicated in the changes of fat body
48 mass (FBM), lean body mass (LBM) and bone fragility induced by ADT. The objective of this study is to
49 correlate FSH serum levels with body composition parameters, bone mineral density (BMD) and bone
50 turnover markers at baseline conditions and after 12 months of ADT.

51 *Methods:* 29 consecutive non-metastatic prostate cancer (PC) patients were enrolled from 2017 to 2019 in
52 a phase IV study. All patients underwent administration of the Luteinizing Hormone-Releasing Hormone
53 antagonist degarelix. FBM, LBM and BMD were evaluated by dual-energy x-ray absorptiometry at baseline
54 and after 12 months of ADT. FSH, alkaline phosphatase (ALP) and C-terminal telopeptide of type I collagen
55 (CTX) were assessed at baseline and after 6 and 12 months. For outcome measurements and statistical
56 analysis, T-test or sign test and Pearson or Spearman tests for continuous variables were used when
57 indicated.

58 *Results:* At baseline conditions, a weak, non-significant, direct relationship was found between FSH serum
59 levels and FBM at arms ($r=0.36$) and legs ($r=0.33$). Conversely, a stronger correlation was observed between
60 FSH and total FBM ($r=0.52$, $p=0.006$), fat mass at arms ($r=0.54$, $p=0.004$) and fat mass at trunk ($r=0.45$,
61 $p=0.018$) assessed after 12 months. On the other hand, an inverse relationship between serum FSH and
62 appendicular lean mass index (ALMI)/FBM ratio was observed ($r=0.64$, $p=0.001$). This is an ancillary study of
63 a prospective trial and this is the main limitation.

64 *Conclusions:* FSH serum levels after ADT could have an impact on body composition, in particular on fat
65 body mass. Therefore, FSH could be a promising marker to monitor the risk of sarcopenic obesity and
66 cardiovascular complications in PC patients undergoing ADT.

67 *Funding:* this research was partially funded by Ferring Pharmaceuticals. The funder had no role in
68 design and conduct of the study, collection, management, analysis, and interpretation of the data
69 and in preparation, review, or approval of the manuscript.

70
71 *Clinical trial number:* [clinicalTrials.gov NCT03202381](https://clinicaltrials.gov/ct2/show/study/NCT03202381), EudraCT Number 2016-004210-10.

73 **Introduction**

74 Recent preclinical and clinical studies have shown that Follicle-Stimulating Hormone (FSH) exerts effects
75 beyond those on gonadal tissue, which have been known for a long time (Lizneva et al. 2019). In the animal
76 model, FSH has been observed to stimulate osteoclastic activity and therefore to exert a negative role on
77 bone mass (Sun et al. 2006; Zaidi et al. 2023; Gera et al. 2022). Furthermore, FSH was found to have a
78 positive action on adipocytes and the blockade of FSH induced by antibodies against FSH receptor caused
79 an increase in bone mass and a reduction of body fat (Liu et al. 2017; Rojekar et al. 2023). These preclinical
80 data were confirmed in clinical studies. Large epidemiologic data have shown significant reductions in bone
81 mineral density (BMD) and high resorption rates ~2-3 years prior to menopause, when FSH serum levels
82 are increasing, which is also associated with increased body weight and visceral adiposity (Thurston et al.
83 2009; Senapati et al. 2014). A longitudinal study involving post-menopausal women has shown that
84 increases in circulating FSH levels were associated with greater increases in the percentage of total body
85 fat, total body fat mass and subcutaneous adipose tissue (Mattick et al. 2022). Moreover, clinical studies
86 have found that FSH is also involved in the modulation of lean mass. A large cohort study of
87 perimenopausal women showed that increased FSH concentrations were associated with increasing fat
88 mass and decreasing lean mass measured by bioelectrical impedance analysis (Sowers et al. 2007). Another
89 recent prospective study showed that the indicators of sarcopenia were strongly associated with
90 gonadotropins levels, especially in older men (Guligowska et al. 2021). The impact of FSH on body

91 composition may at least partially explain the observed correlation between FSH levels and the risk of
92 cardiovascular events (Munir et al. 2012; Celestino Catão Da Silva et al. 2013; El Khoudary et al. 2016).

93 Studies clarifying the relationship among FSH, body composition measures and BMD in prostate cancer (PC)
94 patients are lacking. Likewise, the interaction between the variation of FSH serum levels and the
95 modification of these parameters in PC patients undergoing androgen deprivation therapy (ADT) is not
96 known.

97 We recently conducted the BLADE study (Bone mineral mAss Dexa dEgarelix), a prospective phase IV study
98 designed to obtain explorative information on dual-energy x-ray absorptiometry (DXA) measurement
99 changes in lean body mass (LBM) and fat body mass (FBM) in patients with non-metastatic PC treated with
100 degarelix. Data on changes in total LBM and FBM and on the impact of degarelix on BMD and bone
101 turnover markers were recently published (Palumbo et al. 2021; Palumbo et al. 2022).

102 Here we analyse the association of FSH with DXA-assessed FBM, LBM and BMD and bone turnover markers
103 at baseline and after degarelix administration in the patients enrolled in the BLADE study.

104

105 **Patients and methods**

106 *Trial design and endpoints*

107 BLADE is a single-centre, prospective, interventional phase IV study (clinicalTrials.gov NCT03202381,
108 EudraCT Number 2016-004210-10) conducted at the Prostate Cancer Unit of the Azienda Socio Sanitaria
109 Territoriale degli Spedali Civili and Università degli Studi of Brescia. The study was carried out in accordance
110 with the Declaration of Helsinki Principles and Good Clinical Practices and was approved by the Ethics
111 Committee of Brescia (approval number NP2540). All patients provided a written informed consent. Male
112 patients with histologically confirmed PC without bone metastasis at bone scintigraphy, judged eligible to
113 ADT according to current guidelines recommendations (Cornford et al. 2017; Mottet et al. 2017) after a
114 multidisciplinary discussion, were enrolled. Eligibility criteria have been published elsewhere (Palumbo, et
115 al. 2021). Degarelix was administered as a subcutaneous injection with a starting dose of 240 mg, followed
116 by a maintenance dose of 80 mg every 28 days. After 12 months, treatment with degarelix was continued
117 as clinically indicated. DXA measurements for assessing BMD and body composition parameters were
118 performed at baseline and after 12 months, using Hologic QDR-4500W instrumentation (Hologic
119 Corporation, Waltham, Massachusetts).

120 *Assessment of regional lean body mass and fat body mass by dual x-ray absorptiometry*

121 DXA measurements related to whole body DXA scans were extracted from Apex Software version 3.4.

122 The densitometric image of each patient was divided, following the manufacturer's instructions, into
123 different body districts, including arms, legs, trunk, head and other derived regions, such as the android and
124 gynoid zone.

125 BMD, bone mineral content (BMC), Fat Free Mass and Fat mass were assessed for every region of interest,
126 where Fat Free Mass was provided by the software in terms of lean soft tissue plus BMC. Despite the lean
127 mass measured by DXA counts also skin, connective tissue and some lean components within the adipose
128 tissue (Visser et al. 1999), it still correlates highly with computed tomography and magnetic resonance
129 imaging measurements and represents a good approximation of the real muscle mass (Buckinx et al. 2018).

130 Other DXA derived body composition parameters, such as fat mass index (FM/H²) (FMI), appendicular lean
131 mass index (ALM/H²) (ALMI) and Trunk/Appendicular ratio, were then calculated to complete the analysis
132 and the patient characterization.

133 *Circulating bone turnover markers*

134 Blood chemistry and bone turnover markers: alkaline phosphatase (ALP) and C-terminal telopeptide of type
135 I collagen (CTX) were assessed at baseline, 6 and 12 months. CTX serum levels were measured using the
136 ElectroChemiLuminescenceAssay (ECLIA) kit Elecsys beta-CrossLaps/serum (Roche Diagnostic, Germany)
137 using Cobas e411instruments (Roche); normal ranges were < 0.704 ng/ml (men of the age between 50-70),
138 < 0.854 ng/ml (men > 70) with a repeatability CV% of 2.6. Bone-ALP serum levels were determined in a
139 twostep procedure. Briefly, total ALP serum activity was measured using the colorimetric method ALP2
140 (Roche) using Cobas c701 instruments (Roche); normal ranges were 50-116 U/L +/- 0.6 with a repeatability
141 CV% of 0.7. Samples were then subjected to electrophoretic separation to separate the different ALP
142 isoforms using the G26 automated system (Sebia, France) equipped with the Interlab specific kit (Italy).
143 Bone-ALP activity was calculated as fraction of the total ALP activity related to the percentage of
144 densitometric analysis of the electrophoretic migration

145 *Statistical analysis*

146 The normal distribution of continuous variables was tested with the Shapiro-Wilk test. Differences between
147 parameters at baseline and 12 months were computed as percentage changes. To test if these changes
148 were significantly different from 0 we used one sample t-test, or alternatively the non-parametric sign test.

149 Correlations between variables either at baseline and 12 months were expressed as Pearson's r (or
150 alternatively with Spearman R, for variables not normally distributed).

151 We considered a significant threshold of $p < 0.05$, and to control for possible false positive results we
152 applied the Bonferroni correction ($p' = \frac{p}{k}$, where k is the number of hypotheses tested). Given that Type I
153 errors cannot decrease (the whole point of Bonferroni adjustments) without inflating type II errors
154 (Perneger 1998), significant results in the raw test but which do not remain so after correction will still be
155 mentioned.

156 Statistics were performed using R and SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for Windows,
157 Version 23.0. Armonk, NY: IBM Corp.)

158

159 **Results**

160 Twenty-nine patients were included in the BLADE study and their characteristics have been described
161 elsewhere (Palumbo, et al. 2022). The consort diagram is reported in supplementary material (Figure 1S).

162 Mean FSH serum levels at baseline conditions were 11.9 UI/L (95% Confidence Intervals [CIs]: 7.6 to 16.3).

163 Mean FSH serum levels significantly decreased to 1.45 UI/L (95% CIs: 1.01 to 1.89) after 6 months of
164 degarelix treatment and to 2.4 UI/L (95% CIs: 1.4 to 3.4) after 12 months. The corresponding percent
165 changes were -77.59% (95% CIs: -86.20 to -68.87) and -59.7% (95% CIs: -80.3 to -39.1, $p < 0.001$) (**Figure 1**).

166 Data on changes in body composition parameters, BMD and bone turnover markers have been published
167 elsewhere (Palumbo, et al. 2021; Palumbo, et al. 2022; Dalla Volta et al. 2023). Correlations between FSH

168 changes and changes in body composition parameters, BMD and bone turnover markers were not
169 statistically significant, so these data are not presented.

170 *Relationship between FSH serum levels and body composition, BMD and bone turnover markers at baseline*

171 At baseline conditions no relationship was found between FSH serum levels and the following DXA-derived
172 parameters: BMD at left hip and spine, total FBM, total LBM, lean mass at arms and legs, ALMI, ALMI/FBM
173 ratio and android/gynoid ratio. No correlation was also found between FSH serum levels and serum levels
174 of either ALP or CTX. A direct relationship, although not significant, was found between FSH serum levels
175 and FBM at arms ($r=0.36$) and legs ($r=0.33$) (**Table 1**).

176 *Relationship between FSH serum levels and body composition, BMD and bone turnover markers after 12 177 months of degarelix treatment*

178 The correlation between circulating FSH levels at 6 and 12 months, bone turnover markers evaluated at the
179 same time, BMD and body composition parameters assessed after 12 months is shown in **Table 2**. FSH
180 serum levels assessed after 6 months of degarelix administration showed a direct relationship with total
181 FBM ($r=0.49$, $p=0.008$) and with fat mass evaluated at arms ($r=0.53$, $p=0.004$), trunk ($r=0.48$, $p=0.009$) and
182 legs ($r=0.45$, $p=0.015$). By contrast, FSH serum levels after 6 months of treatment showed an inverse
183 relationship with ALMI/FBM ratio ($r=-0.58$, $p=0.001$). FSH measured after 12 months maintained a
184 significant relationship with total FBM ($r=0.52$, $p=0.006$) (**Figure 2A**), fat mass at arms ($r=0.54$, $p=0.004$)
185 (**Figure 2B**) and fat mass at trunk ($r=0.45$, $p=0.018$) (**Figure 2C**). The relationship between FSH and fat mass
186 at legs lost the statistical significance ($r=0.33$, $p=0.089$), while the inverse relationship with ALMI/FBM ratio
187 was confirmed ($r=0.64$, $p=0.001$) (**Figure 2D**).

188

189 **Discussion**

190 ADT in PC patients leads to an increase in fat mass and to a decrease in lean mass, thus increasing the risk
191 of sarcopenic obesity. In addition, ADT has also a negative impact on skeletal fragility, which increases the
192 risk of fractures. During the recent years, there has been consistent evidence that alterations in body
193 composition could contribute to determine skeletal fragility in patients under ADT, such as well
194 demonstrated in other forms of male hypogonadism (Vena et al. 2022). However, the determinants of
195 altered body composition in male hypogonadism and in ADTs have not been completely defined. As a
196 matter of fact, low testosterone values do not seem to be the only determinant of sarcopenic obesity in
197 males with hypogonadism. In this context, FSH values might play a role. In fact, amongst its extragonadal
198 effects, FSH directly affects adipogenesis, lean mass and bone turnover (Liu, et al. 2017; Rojekar, et al.
199 2023; Zaidi, et al. 2023; Gera, et al. 2022).

200 As demonstrated in other studies prospectively evaluating circulating FSH levels after treatment with
201 Luteinizing Hormone-Releasing Hormone (LHRH) agonists and antagonists (Klotz et al. 2008), degarelix
202 administration consistently reduced FSH values. Therefore, it is reasonable to hypothesize that this
203 hormone is involved in the mechanisms that underlie ADT impact on body composition and skeletal
204 fragility.

205 This ancillary analysis of the BLADE study shows that FSH serum levels correlated with fat mass in basal
206 conditions, albeit not significantly. However, either total fat mass and fat mass in the upper limbs and trunk
207 significantly correlated with FSH values after 12 months of degarelix therapy.

208 Even more interesting, when assessed after degarelix, FSH levels inversely correlated with ALMI/FBM ratio,
209 a parameter that identifies patients at high risk for sarcopenic obesity. These data suggest that sexual
210 hormones counteract FSH effect on body composition at baseline conditions, whereas this effect becomes
211 more evident after ADT.

212 It is noteworthy that FSH values and body composition parameters after 12 months of degarelix therapy
213 achieved a significant correlation, despite the narrow range of FSH levels (**Figure 1**). According to these
214 data, small changes in FSH can result in significant changes in body composition in a condition of androgen
215 and estrogen deprivation.

216 It is known that one of the most noticeable differences of LHRH-antagonists compared to LHRH-agonists
217 are FSH levels during therapy, which are mildly higher with LHRH-agonists compared to LHRH-antagonists.
218 According to our data, PC patients treated with LHRH-antagonists may experience less body composition
219 changes due to lower FSH residual values (Klotz, et al. 2008; Margel et al. 2019; Abufaraj et al. 2021).

220 Unlike other settings, FSH values before and after degarelix did not correlate with either BMD or bone
221 turnover markers.

222 To our knowledge, this is the first study showing an association between circulating FSH levels and body
223 composition in PC patients undergoing ADT. However, this study suffers from all the limitations of ancillary
224 studies. Therefore, the results obtained are to be considered as hypothesis-generating and cannot be
225 generalized.

226 In conclusion, the findings of this study suggest that FSH serum levels after ADT could impact body
227 composition - fat body mass in particular - in PC patients undergoing ADT.

228 Of course further investigation is required to establish the association between FSH serum levels, measured
229 during ADT, and sarcopenic obesity risk in PC patients. However, this is an area of great interest.

230 FSH could be a promising marker in monitoring PC patients during ADT in order to identify those who are
231 more vulnerable and at greater risk of cardiovascular complications.

232

233 **Statements**

234 *Ethical approval:* the study was carried out in accordance with the Declaration of Helsinki Principles and
235 Good Clinical Practices and was approved by the Ethics Committee of Brescia (approval number NP2540).
236 All patients provided a written informed consent.

237

238 *Funding:* this research was partially funded by Ferring Pharmaceuticals. The funder had no role in
239 design and conduct of the study, collection, management, analysis, and interpretation of the data
240 and in preparation, review, or approval of the manuscript.

241

242 *Conflict of interest statement:* Alberto Dalla Volta received grants from Janssen Cylag, Ipsen, support for
243 attending meetings and fee for board from Janssen Cylag; Luca Triggiani received honoraria from Astellas,
244 Janssen and Bayer, support for attending meeting from Janssen; Luca Rinaudo is affiliated with Tecnologie
245 Avanzate S.r.l., the author has no financial interests to declare; Paolo Borghetti received honoraria for
246 lectures from Astrazeneca and Roche; Andrea Guerini received support for attending meeting from Elekta;
247 Davide Farina received consulting fees from Siemens Healthineers; Alessandro Antonelli received payments
248 for clinical trial from Janssen, fees for advisory board from Astra Zeneca, Ipsen, Photocure, Teleflex;
249 Gherardo Mazziotti received fee for preceptorship from Amgen UCB; Alfredo Berruti received consulting
250 fee from Ferring Pharmaceuticals; Marco Bergamini, Carlotta Palumbo, Stefania Zamboni, Manuel
251 Zamparini, Marta Laganà, Nunzia Di Meo, Irene Caramella, Roberto Bresciani, Francesca Valcamonico and
252 Claudio Simeone declare that they have no conflict of interest.

253

254 *Acknowledgements:* the authors are grateful to the following associations: AOB (Associazione
255 Oncologica Bresciana) and FIRM-Onlus (Fondazione Internazionale di Ricerca in Medicina Onlus) for
256 the continuous support.

257

258 **References**

259 Abufaraj, M., T. Iwata, S. Kimura, A. Haddad, H. Al-Ani, L. Abusubaih, M. Moschini, A. Briganti, P. I.
260 Karakiewicz, and S. F. Shariat. 2021. "Differential Impact of Gonadotropin-Releasing Hormone
261 Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic
262 Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials." *Eur Urol* 79, no. 1 (Jan): 44-53.
263 <https://dx.doi.org/10.1016/j.eururo.2020.06.002>.

264

265 Buckinx, F., F. Landi, M. Cesari, R. A. Fielding, M. Visser, K. Engelke, S. Maggi, E. Dennison, N. M. Al-Daghri,
266 S. Allepaerts, J. Bauer, I. Bautmans, M. L. Brandi, O. Bruyère, T. Cederholm, F. Cerreta, A. Cherubini,
267 C. Cooper, A. Cruz-Jentoft, E. McCloskey, B. Dawson-Hughes, J. M. Kaufman, A. Laslop, J.
268 Petermans, J. Y. Reginster, R. Rizzoli, S. Robinson, Y. Rolland, R. Rueda, B. Vellas, and J. A. Kanis.
269 2018. "Pitfalls in the Measurement of Muscle Mass: A Need for a Reference Standard." *J Cachexia*
270 *Sarcopenia Muscle* 9, no. 2 (04): 269-278. <https://dx.doi.org/10.1002/jcsm.12268>.

271

272 Celestino Catão Da Silva, D., A. Nogueira De Almeida Vasconcelos, J. Cleto Maria Cerqueira, D. De Oliveira
273 Cipriano Torres, A. C. Oliveira Dos Santos, H. De Lima Ferreira Fernandes Costa, and L. O. Bregieiro
274 Fernandes Costa. 2013. "Endogenous Sex Hormones Are Not Associated with Subclinical
275 Atherosclerosis in Menopausal Women." *Minerva Ginecol* 65, no. 3 (Jun): 297-302.

276

277 Cornford, P., J. Bellmunt, M. Bolla, E. Briers, M. De Santis, T. Gross, A. M. Henry, S. Joniau, T. B. Lam, M. D.
278 Mason, H. G. van der Poel, T. H. van der Kwast, O. Rouvière, T. Wiegel, and N. Mottet. 2017. "Eau-
279 Estro-Siog Guidelines on Prostate Cancer. Part Ii: Treatment of Relapsing, Metastatic, and
280 Castration-Resistant Prostate Cancer." *Eur Urol* 71, no. 4 (04): 630-642.
281 <https://dx.doi.org/10.1016/j.eururo.2016.08.002>.

282

283 Dalla Volta, A., C. Palumbo, S. Zamboni, G. Mazziotti, L. Triggiani, M. Zamparini, F. Maffezzoni, L. Rinaudo,
284 M. Bergamini, N. Di Meo, I. Caramella, F. Valcamonico, P. Borghetti, A. Guerini, D. Farina, A.
285 Antonelli, C. Simeone, and A. Berruti. 2023. "Heterogeneity in Regional Changes in Body
286 Composition Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: Potential
287 Impact on Bone Health-the Blade Study." *J Endocrinol Invest* (Jul 17).
288 <https://dx.doi.org/10.1007/s40618-023-02150-z>.

289

290 El Khoudary, S. R., N. Santoro, H. Y. Chen, P. G. Tepper, M. M. Brooks, R. C. Thurston, I. Janssen, S. D.
291 Harlow, E. Barinas-Mitchell, F. Selzer, C. A. Derby, E. A. Jackson, D. McConnell, and K. A. Matthews.
292 2016. "Trajectories of Estradiol and Follicle-Stimulating Hormone over the Menopause Transition
293 and Early Markers of Atherosclerosis after Menopause." *Eur J Prev Cardiol* 23, no. 7 (May): 694-703.
294 <https://dx.doi.org/10.1177/2047487315607044>.

295

296 Gera, S., T. C. Kuo, A. A. Gumerova, F. Korkmaz, D. Sant, V. DeMambro, K. Sudha, A. Padilla, G. Prevot, J.
297 Munitz, A. Teunissen, M. M. T. van Leent, T. G. J.M Post, J. C. Fernandes, J. Netto, F. Sultana, E.
298 Shelly, S. Rojekar, P. Kumar, L. Cullen, J. Chatterjee, A. Pallapati, S. Miyashita, H. Kannangara, M.

- 299 Bhongade, P. Sengupta, K. Ievleva, V. Muradova, R. Batista, C. Robinson, A. Macdonald, S.
300 Hutchison, M. Saxena, M. Meseck, J. Caminis, J. Iqbal, M. I. New, V. Ryu, S. M. Kim, J. J. Cao, N.
301 Zaidi, Z. A. Fayad, D. Lizneva, C. J. Rosen, T. Yuen, and M. Zaidi. 2022. "Fsh-Blocking Therapeutic for
302 Osteoporosis." *Elife* 11 (Sep 20). <https://dx.doi.org/10.7554/eLife.78022>.
- 303
304 Guligowska, A., Z. Chrzastek, M. Pawlikowski, M. Pięłowska, H. Pisarek, K. Winczyk, and T. Kostka. 2021.
305 "Gonadotropins at Advanced Age - Perhaps They Are Not So Bad? Correlations between
306 Gonadotropins and Sarcopenia Indicators in Older Adults." *Front Endocrinol (Lausanne)* 12: 797243.
307 <https://dx.doi.org/10.3389/fendo.2021.797243>.
- 308
309 Klotz, L., L. Boccon-Gibod, N. D. Shore, C. Andreou, B. E. Persson, P. Cantor, J. K. Jensen, T. K. Olesen, and F.
310 H. Schröder. 2008. "The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized,
311 Open-Label, Parallel-Group Phase Iii Study in Patients with Prostate Cancer." *BJU Int* 102, no. 11
312 (Dec): 1531-8. <https://dx.doi.org/10.1111/j.1464-410X.2008.08183.x>.
- 313
314 Liu, P., Y. Ji, T. Yuen, E. Rendina-Ruedy, V. E. DeMambro, S. Dhawan, W. Abu-Amer, S. Izadmehr, B. Zhou, A.
315 C. Shin, R. Latif, P. Thangeswaran, A. Gupta, J. Li, V. Shnyder, S. T. Robinson, Y. E. Yu, X. Zhang, F.
316 Yang, P. Lu, Y. Zhou, L. L. Zhu, D. J. Oberlin, T. F. Davies, M. R. Reagan, A. Brown, T. R. Kumar, S.
317 Epstein, J. Iqbal, N. G. Avadhani, M. I. New, H. Molina, J. B. van Klinken, E. X. Guo, C. Buettner, S.
318 Haider, Z. Bian, L. Sun, C. J. Rosen, and M. Zaidi. 2017. "Blocking Fsh Induces Thermogenic Adipose
319 Tissue and Reduces Body Fat." *Nature* 546, no. 7656 (06 01): 107-112.
320 <https://dx.doi.org/10.1038/nature22342>.
- 321
322 Lizneva, D., A. Rahimova, S. M. Kim, I. Atabekov, S. Javaid, B. Alamoush, C. Taneja, A. Khan, L. Sun, R. Azziz,
323 T. Yuen, and M. Zaidi. 2019. "Fsh Beyond Fertility." *Front Endocrinol (Lausanne)* 10: 136.
324 <https://dx.doi.org/10.3389/fendo.2019.00136>.
- 325
326 Margel, D., A. Peer, Y. Ber, L. Shavit-Grievink, T. Tabachnik, S. Sela, G. Witberg, J. Baniel, D. Kedar, W. C. M.
327 Duivenvoorden, E. Rosenbaum, and J. H. Pinthus. 2019. "Cardiovascular Morbidity in a Randomized
328 Trial Comparing GnRh Agonist and GnRh Antagonist among Patients with Advanced Prostate Cancer
329 and Preexisting Cardiovascular Disease." *J Urol* 202, no. 6 (Dec): 1199-1208.
330 <https://dx.doi.org/10.1097/JU.0000000000000384>.
- 331
332 Mattick, L. J., J. W. Bea, L. Singh, K. M. Hovey, H. R. Banack, J. Wactawski-Wende, J. E. Manson, J. L. Funk,
333 and H. M. Ochs-Balcom. 2022. "Serum Follicle-Stimulating Hormone and 5-Year Change in Adiposity
334 in Healthy Postmenopausal Women." *J Clin Endocrinol Metab* 107, no. 8 (07 14): e3455-e3462.
335 <https://dx.doi.org/10.1210/clinem/dgac238>.
- 336
337 Mottet, N., J. Bellmunt, M. Bolla, E. Briers, M. G. Cumberbatch, M. De Santis, N. Fossati, T. Gross, A. M.
338 Henry, S. Joniau, T. B. Lam, M. D. Mason, V. B. Matveev, P. C. Moldovan, R. C. N. van den Bergh, T.
339 Van den Broeck, H. G. van der Poel, T. H. van der Kwast, O. Rouvière, I. G. Schoots, T. Wiegel, and P.
340 Cornford. 2017. "Eau-Estro-Siog Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and
341 Local Treatment with Curative Intent." *Eur Urol* 71, no. 4 (04): 618-629.
342 <https://dx.doi.org/10.1016/j.eururo.2016.08.003>.
- 343
344 Munir, J. A., H. Wu, K. Bauer, J. Bindeman, C. Byrd, I. M. Feuerstein, T. C. Villines, and A. J. Taylor. 2012.
345 "The Perimenopausal Atherosclerosis Transition: Relationships between Calcified and Noncalcified

- 346 Coronary, Aortic, and Carotid Atherosclerosis and Risk Factors and Hormone Levels." *Menopause*
347 19, no. 1 (Jan): 10-5. <https://dx.doi.org/10.1097/gme.0b013e318221bc8d>.
- 348
349 Palumbo, C., A. Antonelli, L. Triggiani, A. Dalla Volta, F. Maffezzoni, S. Zamboni, P. Borghetti, L. Rinaudo, F.
350 Valcamonico, R. Maroldi, S. M. Magrini, C. Simeone, A. Berruti, and Collaborators. 2021. "Changes
351 in Body Composition and Lipid Profile in Prostate Cancer Patients without Bone Metastases Given
352 Degarelix Treatment: The Blade Prospective Cohort Study." *Prostate Cancer Prostatic Dis* 24, no. 3
353 (09): 852-859. <https://dx.doi.org/10.1038/s41391-021-00345-0>.
- 354
355 Palumbo, C., A. Dalla Volta, S. Zamboni, G. Mazziotti, M. Zamparini, L. Triggiani, P. Borghetti, F. Maffezzoni,
356 R. Bresciani, L. Rinaudo, F. Valcamonico, D. Farina, S. M. Magrini, A. Antonelli, C. Simeone, and A.
357 Berruti. 2022. "Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients
358 without Bone Metastases. The Blade Study." *J Clin Endocrinol Metab* (Aug 16).
359 <https://dx.doi.org/10.1210/clinem/dgac489>.
- 360
361 Perneger, T. V. 1998. "What's Wrong with Bonferroni Adjustments." *BMJ* 316, no. 7139 (Apr 18): 1236-8.
362 <https://dx.doi.org/10.1136/bmj.316.7139.1236>.
- 363
364 Rojekar, S., A. R. Pallapati, J. Gimenez-Roig, F. Korkmaz, F. Sultana, D. Sant, C. M. Haeck, A. Macdonald, S.
365 M. Kim, C. J. Rosen, O. Barak, M. Meseck, J. Caminis, D. Lizneva, T. Yuen, and M. Zaidi. 2023.
366 "Development and Biophysical Characterization of a Humanized Fsh-Blocking Monoclonal Antibody
367 Therapeutic Formulated at an Ultra-High Concentration." *Elife* 12 (Jun 19).
368 <https://dx.doi.org/10.7554/eLife.88898>.
- 369
370 Senapati, S., C. R. Gracia, E. W. Freeman, M. D. Sammel, H. Lin, C. Kim, R. J. Schwab, and G. W. Pien. 2014.
371 "Hormone Variations Associated with Quantitative Fat Measures in the Menopausal Transition."
372 *Climacteric* 17, no. 2 (Apr): 183-90. <https://dx.doi.org/10.3109/13697137.2013.845876>.
- 373
374 Sowers, M., H. Zheng, K. Tomey, C. Karvonen-Gutierrez, M. Jannausch, X. Li, M. Yosef, and J. Symons. 2007.
375 "Changes in Body Composition in Women over Six Years at Midlife: Ovarian and Chronological
376 Aging." *J Clin Endocrinol Metab* 92, no. 3 (Mar): 895-901. <https://dx.doi.org/10.1210/jc.2006-1393>.
- 377
378 Sun, L., Y. Peng, A. C. Sharrow, J. Iqbal, Z. Zhang, D. J. Papachristou, S. Zaidi, L. L. Zhu, B. B. Yaroslavskiy, H.
379 Zhou, A. Zallone, M. R. Sairam, T. R. Kumar, W. Bo, J. Braun, L. Cardoso-Landa, M. B. Schaffler, B. S.
380 Moonga, H. C. Blair, and M. Zaidi. 2006. "Fsh Directly Regulates Bone Mass." *Cell* 125, no. 2 (Apr
381 21): 247-60. <https://dx.doi.org/10.1016/j.cell.2006.01.051>.
- 382
383 Thurston, R. C., M. R. Sowers, B. Sternfeld, E. B. Gold, J. Bromberger, Y. Chang, H. Joffe, C. J. Crandall, L. E.
384 Waetjen, and K. A. Matthews. 2009. "Gains in Body Fat and Vasomotor Symptom Reporting over
385 the Menopausal Transition: The Study of Women's Health across the Nation." *Am J Epidemiol* 170,
386 no. 6 (Sep 15): 766-74. <https://dx.doi.org/10.1093/aje/kwp203>.
- 387
388 Vena, W., F. Carrone, A. Delbarba, O. Akpojiovbi, L. C. Pezzaioli, P. Facondo, C. Cappelli, L. Leonardi, L.
389 Balzarini, D. Farina, A. Pizzocaro, A. G. Lania, G. Mazziotti, and A. Ferlin. 2022. "Body Composition,
390 Trabecular Bone Score and Vertebral Fractures in Subjects with Klinefelter Syndrome." *J Endocrinol*
391 *Invest* (Aug 28). <https://dx.doi.org/10.1007/s40618-022-01901-8>.

392

393 Visser, M., T. Fuerst, T. Lang, L. Salamone, and T. B. Harris. 1999. "Validity of Fan-Beam Dual-Energy X-Ray
394 Absorptiometry for Measuring Fat-Free Mass and Leg Muscle Mass. Health, Aging, and Body
395 Composition Study--Dual-Energy X-Ray Absorptiometry and Body Composition Working Group." *J*
396 *Appl Physiol (1985)* 87, no. 4 (Oct): 1513-20. <https://dx.doi.org/10.1152/jappl.1999.87.4.1513>.

397

398 Zaidi, M., S. M. Kim, M. Mathew, F. Korkmaz, F. Sultana, S. Miyashita, A. A. Gumerova, T. Frolinger, O.
399 Moldavski, O. Barak, A. Pallapati, S. Rojekar, J. Caminis, Y. Ginzburg, V. Ryu, T. F. Davies, D. Lizneva,
400 C. J. Rosen, and T. Yuen. 2023. "Bone Circuitry and Interorgan Skeletal Crosstalk." *Elife* 12 (Jan 19).
401 <https://dx.doi.org/10.7554/eLife.83142>.

402

403

TABLE 1

Table 1 – Baseline relationships between FSH serum levels and BMD, bone turnover markers and body composition parameters.

	FSH	
	Correlation coefficient	p
TOT BMD	.240	.218
BMD LEFT HIP	.229	.240
BMD L2-L4	.148	.453
CTX	-.115	.560
BONE ALP	.001	.997
TOT Fat (g)	.274	.158
Arm Fat (g)	.363	.058
Leg Fat (g)	.330	.087
Head Fat (g)	.228	.244
Trunk Fat (g)	.249	.202
TOT Lean (g)	.216	.270
Arm Lean (g)	.166	.400
Leg Lean (g)	.197	.315
Head Lean (g)	.250	.199
Trunk Lean (g)	.190	.333
ALMI (Appendicular Lean/Ht²)	.269	.167
ALMI/FBM	-.184	.349
Android/Gynoid Ratio	-.024	.902

FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht²: height squared; FBM: fat body mass.
Data are Spearman R.

TABLE 2

Table 2 – Relationships between FSH serum levels and BMD, bone turnover markers and body composition parameters after 12-months degarelix treatment.

	FSH at 6 months		FSH at 12 months	
	Correlation coefficient	p	Correlation coefficient	p
TOT BMD	-.039	.843	-.107	.595
BMD L2-L4	.102	.604	-.040	.844
BMD LEFT HIP	.030	.881	-.044	.829
CTX	.051	.796	.055	.785
BONE ALP	.174	.376	.227	.256
TOT Fat (g)	.490	.008	.518	.006
Arm Fat (g)	.532	.004	.541	.004
Leg Fat (g)	.454	.015	.328	.089
Head Fat (g)	.187	.341	.093	.644
Trunk Fat (g)	.483	.009	.452	.018
TOT Lean (g)	.029	.885	-.036	.859
Arm Lean (g)	.041	.837	.028	.889
Leg Lean (g)	-.176	.371	-.285	.149
Head Lean (g)	.086	.663	-.006	.977
Trunk Lean (g)	.161	.414	.021	.916
ALMI (Appendicular Lean/Ht ²)	-.229	.241	-.265	.181
ALMI/FBM	-.581	.001*	-.604	.001*
Android/Gynoid Ratio	.142	.472	.231	.246

FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht²: height squared; FBM: fat body mass.

Data are Spearman R.

*Still significant after Bonferroni correction.

FIGURE 1
Estimate differences in FSH






Figure 1 – Changes in mean follicle-stimulating hormone (FSH) serum levels from baseline to 6 and 12 months of degarelix treatment.

FIGURE 2


2a



2b



2c



2d




Figure 2 – Relationship between follicle-stimulating hormone (FSH) serum levels and fat body mass (FBM) (**Fig. 2a**), arm fat body mass (**Fig. 2b**), trunk fat body mass (**Fig. 2c**) and appendicular lean mass index (ALMI)/FBM ratio (**Fig. 2d**) after 12-months degarelix treatment.

R = Spearman correlation coefficient; p = p-value.

CONSORT DIAGRAM (source data [123547_0_data_set_3007640_s1333z.xls](#))

